Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Large B Cell Lymphoma: early-phase trial registry
53 of 115 indexed Diffuse Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #110 of 28,707 conditions by registered trial count.
115 US clinical trials · 53 currently recruiting · #110 of 28,707 conditions by registered trial count
Diffuse Large B Cell Lymphoma: 115 US clinical trials tracked, 53 recruiting.
Diffuse Large B Cell Lymphoma is the subject of 115 registered US clinical trials on ClinicalTrials.gov, 53 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most active sponsor is Genmab, running 6 of these trials.
Enrollment posture brief
Registry condition diffuse-large-b-cell-lymphoma
OPEN 53 | RECR 46% | LATE 11 | EARLY 88 | RANK #110 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Recurrent Glioblastoma (46% recruiting · 63 trials)
Diffuse Large B Cell Lymphoma lists 53 open slots (46% of 115 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Large B Cell Lymphoma is recruiting above its size-band peers.
53 of 115 indexed trials (46.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diffuse Large B Cell Lymphoma trials is spread across many organizations.
Genmab accounts for 6 of 115 trials (5.2%). 77 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Large B Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 115 trials that report a genuine target (sentinel values excluded). 72 of those (62.6%) plan for fewer than 100 participants.
-
Diffuse Large B Cell Lymphoma research is mostly interventional.
107 interventional and 8 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
115 total, page 3 of 3
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Sanofi
NCT01472887
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University of Southern California
NCT00599170
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
Carevive Systems
NCT04160442
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT03019666
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
Hoffmann-La Roche
NCT03255096
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT01234467
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01314014
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Acrotech Biopharma
NCT01851551
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Fox Chase Cancer Center
NCT03311958
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
NCT03742258
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
NCT06004167
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Kymera Therapeutics
NCT05233033
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT04323657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 30 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Large B Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Large B Cell Lymphoma page
115 registered trials, 53 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 53 Diffuse Large B Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genmab sponsors the most Diffuse Large B Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Genmab's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Large B Cell Lymphoma condition card totals 115 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.